Sign in
Join
Home
About Us
Privacy Policy
Disclaimer
Advertise On Market Exclusive
Sitemap
Submit a Scoop!
Contact Us
Stock Market News
Stocks
Analyst Ratings
Insider Trading
SEC Filings
Earnings
Cannabis Stocks News
Biotech Stocks
Small Caps
Blockchain & Cryptocurrency
Become a Contributor!
Sign in
Welcome!
Log into your account
your username
your password
Forgot your password?
Sign up
Welcome!
Register for an account
your email
your username
A password will be e-mailed to you.
Password recovery
Recover your password
your email
Search
Sign in / Join
My Account
orders
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Create an account
Create an account
Welcome! Register for an account
your email
your username
A password will be e-mailed to you.
Password recovery
Recover your password
your email
A password will be e-mailed to you.
Market Exclusive
Home
About Us
Privacy Policy
Disclaimer
Advertise On Market Exclusive
Sitemap
Submit a Scoop!
Contact Us
Stock Market News
Stocks
Analyst Ratings
Insider Trading
SEC Filings
Earnings
Cannabis Stocks News
Biotech Stocks
Small Caps
Blockchain & Cryptocurrency
Become a Contributor!
Home
Tags
Sarepta
Tag: Sarepta
Here’s Why Capricor Therapeutics Inc (NASDAQ:CAPR) Is Running This Week
ME Contributor
-
September 20, 2017
0
Sarepta Therapeutics Inc (NASDAQ:SRPT) Gets Off To A Running Start With...
ME Contributor
-
January 11, 2017
0
Why the Performance of Sarepta Therapeutics Inc. (NASDAQ:SRPT) Eteplirsen Could Determine...
Rafi Farber
-
September 19, 2016
0
Summit Therapeutics PLC (ADR) (NASDAQ:SMMT) Is Hot On Sarepta Therapeutics Inc...
ME Contributor
-
June 21, 2016
0
Weekly Biotech Report on Sarepta Therapeutics (NASDAQ:SRPT) Battle with FDA on...
David Rich
-
May 31, 2016
0
Weekly Biotech Report – Covering – Acadia Pharmaceuticals Inc. (NASDAQ:ACAD), Kempharm...
David Rich
-
May 2, 2016
0
The Week’s Biggest Movers: Aduro BioTech Inc (NASDAQ:ADRO) and Sarepta Therapeutics...
ME Contributor
-
March 11, 2016
0
BioMarin, Sarepta’s Loss Could Be PTC’s Gain
Roger Hannington
-
January 18, 2016
0
Could the FDA Approve Both BioMarin and Sarepta’s DMD Candidates?
Roger Hannington
-
December 17, 2015
0
/* */
// AST – IMS - [MarketExclusive_ROS]